A Phase Ib Trial of Neoadjuvant Low-Dose Radiation Therapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC
Latest Information Update: 13 Oct 2021
At a glance
- Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 13 Oct 2021 New trial record
- 14 Sep 2021 Trial design presented at the 2021 World Conference on Lung Cancer